Skip to main content

Psoriasis News (Page 4)

Related terms: Erythrodermic Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Palmo-plantar Psoriasis, Psoriasis vulgaris, Pustular Psoriasis

Janssen Announces FDA Approval of Tremfya (guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis

Horsham, PA, July 13, 2017 ― Janssen Biotech, Inc. (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for the treatment of adults living with ...

FDA Approves Siliq (brodalumab) for Plaque Psoriasis

February 15, 2017 – The U.S. Food and Drug Administration today approved Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis. Siliq is administered as an injection. Siliq is...

FDA Approves Expanded Use of Enbrel (etanercept) to Treat Children with Chronic Moderate-To-Severe Plaque Psoriasis

THOUSAND OAKS, Calif., Nov. 4, 2016 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application...

FDA Approves Amjevita (adalimumab-atto), a Biosimilar to Humira

September 23, 2016 – The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases. Amjevita is approved...

FDA Approves Inflectra (infliximab-dyyb) a Biosimilar to Remicade

April 5, 2016 – The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second...

FDA Approves Taltz (ixekizumab) for Plaque Psoriasis

March 22, 2016 – The U.S. Food and Drug Administration today approved Taltz (ixekizumab) to treat adults with moderate-to-severe plaque psoriasis. Psoriasis is a skin condition that causes patches...

Promius Pharma Receives FDA Approval for Sernivo (betamethasone dipropionate) Spray

HYDERABAD, India & PRINCETON, N.J., February 07, 2016 --(BUSINESS WIRE)--Dr. Reddy’s announced today that its US subsidiary, Promius Pharma, LLC, U.S. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), has r...

Novartis Receives FDA Approval for Cosentyx (secukinumab) to Treat Patients with Ankylosing Spondylitis and Psoriatic Arthritis

EAST HANOVER, N.J., Jan. 15, 2016 Novartis announced today that the US Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) for two new indications - the treatment of adult...

LEO Pharma Announces U.S. Approval of Enstilar Foam (calcipotriene/betamethasone dipropionate) for Plaque Psoriasis

Ballerup, Denmark 19 October, 2015: LEO Pharma announced today that the U.S. Food and Drug Administration (FDA) has approved Enstilar (calcipotriene/betamethasone dipropionate 50 micrograms/g / 0,5...

FDA Approves Cosentyx (secukinumab) for Plaque Psoriasis

January 21, 2015 – The U.S. Food and Drug Administration today approved Cosentyx (secukinumab) to treat adults with moderate-to-severe plaque psoriasis. Psoriasis is a skin condition that causes...

FDA Approves Otezla (apremilast) for Moderate to Severe Plaque Psoriasis

SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved Otezla (apremilast), the Company's oral, selective inhibitor of...

FDA Approves Rasuvo (methotrexate) Injection

Chicago, IL, July 14, 2014 – Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced...

Otrexup (Methotrexate) Injection Approved By FDA

EWING, N.J., October 14, 2013 — Antares Pharma, Inc. today announced the approval of Otrexup (methotrexate) injection by the U.S. Food and Drug Administration (FDA). Otrexup is the first FDA approved ...

Stiefel, a GSK company, Receives FDA Approval of Sorilux (calcipotriene) Foam, 0.005%

Research Triangle Park, N.C. – October 12, 2010 – Stiefel, a GSK company, today announced that the U.S. Food and Drug Administration (FDA) has approved Sorilux (calcipotriene) Foam, 0.005%, for the to...

FDA Approves Stelara (ustekinumab) to Treat Psoriasis

September 25, 2009 - The U.S. Food and Drug Administration today approved Stelara (ustekinumab), a biologic product for adults who have a moderate to severe form of psoriasis. Plaque psoriasis is an...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Plaque Psoriasis, Dermatological Disorders

Related drug support groups

prednisone, methylprednisolone, methotrexate, Humira, triamcinolone, clobetasol, fluocinonide, Remicade, prednisolone, view more... Stelara, Cosentyx, Skyrizi, adalimumab, etanercept, dexamethasone, desonide, halobetasol, Taltz